Business Description
Enlivex Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011319527
Compare
Compare
Traded in other countries / regions
ENLV.USAENLV.Israel1BT.Germany IPO Date
2014-07-31Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.75 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11.8 | |||||
| 3-Year EPS without NRI Growth Rate | -10.7 | |||||
| 3-Year FCF Growth Rate | -27.8 | |||||
| 3-Year Book Growth Rate | 41.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.4 | |||||
| 9-Day RSI | 20.1 | |||||
| 14-Day RSI | 25.83 | |||||
| 6-1 Month Momentum % | 168.61 | |||||
| 12-1 Month Momentum % | 24.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.34 | |||||
| Quick Ratio | 7.34 | |||||
| Cash Ratio | 7.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.3 | |||||
| Shareholder Yield % | -7.37 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -53.51 | |||||
| ROA % | -45.26 | |||||
| ROIC % | -121.49 | |||||
| ROC (Joel Greenblatt) % | -153.12 | |||||
| ROCE % | -49.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.63 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 0.05 | |||||
| EV-to-EBITDA | 0.05 | |||||
| EV-to-FCF | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.04 | |||||
| Price-to-Net-Cash | 1.1 | |||||
| Earnings Yield (Greenblatt) % | 2000 | |||||
| FCF Yield % | -105.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENLV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enlivex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.47 | ||
| Beta | 1.6 | ||
| Volatility % | 82.07 | ||
| 14-Day RSI | 25.83 | ||
| 14-Day ATR ($) | 0.398467 | ||
| 20-Day SMA ($) | 2.97875 | ||
| 12-1 Month Momentum % | 24.32 | ||
| 52-Week Range ($) | 1.15 - 4.59 | ||
| Shares Outstanding (Mil) | 18.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enlivex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enlivex Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enlivex Therapeutics Ltd Frequently Asked Questions
What is Enlivex Therapeutics Ltd(ENLV)'s stock price today?
The current price of ENLV is $1.32. The 52 week high of ENLV is $4.59 and 52 week low is $1.15.
When is next earnings date of Enlivex Therapeutics Ltd(ENLV)?
The next earnings date of Enlivex Therapeutics Ltd(ENLV) is 2024-06-26 Est..
Does Enlivex Therapeutics Ltd(ENLV) pay dividends? If so, how much?
Enlivex Therapeutics Ltd(ENLV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers